These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 9413099

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R.
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [Abstract] [Full Text] [Related]

  • 5. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, Soncini R.
    Vaccine; 2000 Jun 15; 18(25):2796-803. PubMed ID: 10812221
    [Abstract] [Full Text] [Related]

  • 6. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
    Davidkin I, Valle M, Julkunen I.
    Vaccine; 1995 Nov 15; 13(16):1617-22. PubMed ID: 8578851
    [Abstract] [Full Text] [Related]

  • 7. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A, Gerike E.
    Vaccine; 2000 Jan 31; 18(14):1382-92. PubMed ID: 10618536
    [Abstract] [Full Text] [Related]

  • 8. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G, Peña B, Marimón JM, Pérez-Trallero E.
    Vaccine; 1996 Apr 31; 14(6):492-4. PubMed ID: 8782345
    [Abstract] [Full Text] [Related]

  • 9. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M.
    Vaccine; 1995 Jun 31; 13(9):799-802. PubMed ID: 7483800
    [Abstract] [Full Text] [Related]

  • 10. Serological evaluation of a measles, mumps, and rubella vaccine.
    Robertson CM, Bennett VJ, Jefferson N, Mayon-White RT.
    Arch Dis Child; 1988 Jun 31; 63(6):612-6. PubMed ID: 3291787
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE.
    J Infect Dis; 1996 Mar 31; 173(3):731-4. PubMed ID: 8627041
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
    Reuman PD, Sawyer MH, Kuter BJ, Matthews H.
    Pediatr Infect Dis J; 1997 Jul 31; 16(7):662-7. PubMed ID: 9239770
    [Abstract] [Full Text] [Related]

  • 13. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH, Saracen CL, Peter G.
    Pediatrics; 1994 Oct 31; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [Abstract] [Full Text] [Related]

  • 14. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO, Kapustik LA, Fel'dman EV, Ermolovich MA, Svirchevskaia EIu, Titov LP, Zakharenko DF, Belova EIu, Chernovetskiĭ MA, Korostik TS.
    Zh Mikrobiol Epidemiol Immunobiol; 1998 Oct 31; (4):36-40. PubMed ID: 9783398
    [Abstract] [Full Text] [Related]

  • 15. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
    Usonis V, Bakasenas V, Chitour K, Clemens R.
    Infection; 1998 Oct 31; 26(4):222-6. PubMed ID: 9717679
    [Abstract] [Full Text] [Related]

  • 16. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura.
    Pool V, Chen R, Rhodes P.
    Pediatr Infect Dis J; 1997 Apr 31; 16(4):423-4. PubMed ID: 9109153
    [No Abstract] [Full Text] [Related]

  • 17. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S, Cordero-Yap L, Lu-Fong M, Soriano R, Ludan A, Chitour K, Bock HL.
    Southeast Asian J Trop Med Public Health; 1999 Sep 31; 30(3):511-7. PubMed ID: 10774661
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.
    Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, André FE.
    Acta Paediatr Scand; 1991 Nov 31; 80(11):1051-7. PubMed ID: 1661057
    [Abstract] [Full Text] [Related]

  • 19. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
    Senterre J.
    Rev Med Liege; 1999 Feb 31; 54(2):122-4. PubMed ID: 10221066
    [Abstract] [Full Text] [Related]

  • 20. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.